News Big pharma could turn to viruses to boost cancer immunothera... Norwegian biotech looking for development partners
News Immunotherapy arms race latest: Merck buys Viralytics for $3... Big pharma pays 160% premium for Australian biotech
News US judge overturns Gilead $2.54bn patent infringement ruling Federal judge throws out Merck's patent claim against Gilead
News Concerns mount over Biogen Alzheimer's drug FDA announces guidance to encourage development of new drugs
News BMS makes record $1.8bn bet on Nektar cancer drug Bristol-Myers Squibb scored a first-in-class approval with cancer immunotherapy Opdivo just a few years ago – could it be about repeat the trick with a new drug that stimulates natural kill
News Doubts over BACE drugs after Merck ends Alzheimer's trial Decision comes a year after Merck axed EPOCH verubecestat trial
News ADARx, Trex, and Retension take aim at IPOs The appetite among biotechs for IPOs shows no signs of being satisfied, with three more – ADARx, TRex, and Retension – making their intentions known.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
